Passage Bio scraps a therapy; XOMA’s new loan; Impel is for sale

2023-12-20

基因疗法

Plus, news on ImpriMed, bluebird bio and Syndax.

Passage Bio shakes up its pipeline: The Jim Wilson-founded biotech is shelving a therapy for GM1 gangliosidosis. It now plans to focus on a preclinical Huntington’s gene therapy and a gene therapy for patients with a form of dementia after reporting safety and biomarker data from three patients, potentially testing the treatment in other adult neurodegenerative diseases. Passage this year has gone through a series of leadership changes and layoffs and already sidelined two pediatric gene therapy programs for Krabbe disease and metachromatic leukodystrophy. — Lei Lei Wu

Passage Bio scraps a therapy; XOMA’s new loan; Impel is for sale

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构